Figure 3. Kaplan-Meier analysis of 5-year relapse-free survival (RFS) and 5-year disease-specific survival (DSS) for B-cell Lymphoma 2 (BCL2)-positive and BCL2-negative luminal A breast cancer patients. Patients expressing BCL2 have longer 5-year RFS (A) (p=0.023) and 5-year DSS (B) (p=0.041).